Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

51.01 -1.91 (-3.61%)

Streaming Delayed Price Updated: 3:12 PM EDT, Aug 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	471,793
Open	52.51
Bid (Size)	50.97 (200)
Ask (Size)	51.07 (100)
Prev. Close	52.92
Today's Range	50.69 - 52.68
52wk Range	27.07 - 58.49
Shares Outstanding	94,873,407
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 07, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Q2 Earnings Call Highlights ↗

August 07, 2026

Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the...

Via MarketBeat

Performance

YTD	+19.2%	+19.2%
1 Month	-10.1%	-10.1%
3 Month	+5.5%	+5.5%
6 Month	+6.6%	+6.6%
1 Year	+62.0%	+62.0%

More News

Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results ↗

August 06, 2026

Via Chartmill

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 06, 2026

From Scholar Rock

Via Business Wire

Scholar Rock (SRRK) Q1 Loss Narrows In Line Awaits PDUFA Decision ↗

May 07, 2026

Via Chartmill

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 20, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

July 16, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

June 22, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 12, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

May 20, 2026

From Scholar Rock, Inc.

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026

From Scholar Rock, Inc.

Via Business Wire

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Via The Motley Fool

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Via The Motley Fool

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

Via The Motley Fool

Scholar Rock Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 07, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

April 29, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

March 31, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2026

From Scholar Rock

Via Business Wire

Frequently Asked Questions

Is Scholar Rock Holding Corporation - Common Stock publicly traded?

Yes, Scholar Rock Holding Corporation - Common Stock is publicly traded.

What exchange does Scholar Rock Holding Corporation - Common Stock trade on?

Scholar Rock Holding Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Scholar Rock Holding Corporation - Common Stock?

The ticker symbol for Scholar Rock Holding Corporation - Common Stock is SRRK on the Nasdaq Stock Market

What is the current price of Scholar Rock Holding Corporation - Common Stock?

The current price of Scholar Rock Holding Corporation - Common Stock is 51.01

When was Scholar Rock Holding Corporation - Common Stock last traded?

The last trade of Scholar Rock Holding Corporation - Common Stock was at 08/10/26 03:12 PM ET

What is the market capitalization of Scholar Rock Holding Corporation - Common Stock?

The market capitalization of Scholar Rock Holding Corporation - Common Stock is 4.84B

How many shares of Scholar Rock Holding Corporation - Common Stock are outstanding?

Scholar Rock Holding Corporation - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.